BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23499727)

  • 1. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
    Oliviero B; Mele D; Degasperi E; Aghemo A; Cremonesi E; Rumi MG; Tinelli C; Varchetta S; Mantovani S; Colombo M; Mondelli MU
    J Hepatol; 2013 Jul; 59(1):38-44. PubMed ID: 23499727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
    Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
    Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of NKG2A with treatment for chronic hepatitis C virus infection.
    Harrison RJ; Ettorre A; Little AM; Khakoo SI
    Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.
    Conry SJ; Meng Q; Hardy G; Yonkers NL; Sugalski JM; Hirsch A; Davitkov P; Compan A; Falck-Ytter Y; Blanton RE; Rodriguez B; Harding CV; Anthony DD
    J Infect Dis; 2012 Apr; 205(7):1131-41. PubMed ID: 22351942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection.
    Pár G; Rukavina D; Podack ER; Horányi M; Szekeres-Barthó J; Hegedüs G; Paál M; Szereday L; Mózsik G; Pár A
    J Hepatol; 2002 Oct; 37(4):514-22. PubMed ID: 12217606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.
    Mania A; Kaczmarek M; Kemnitz P; Mazur-Melewska K; Figlerowicz M; Sikora J; Służewski W; Żeromski J
    Med Microbiol Immunol; 2018 Feb; 207(1):55-63. PubMed ID: 29119253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.
    Ahlenstiel G; Edlich B; Hogdal LJ; Rotman Y; Noureddin M; Feld JJ; Holz LE; Titerence RH; Liang TJ; Rehermann B
    Gastroenterology; 2011 Oct; 141(4):1231-9, 1239.e1-2. PubMed ID: 21741920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
    Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
    Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.
    Edlich B; Ahlenstiel G; Zabaleta Azpiroz A; Stoltzfus J; Noureddin M; Serti E; Feld JJ; Liang TJ; Rotman Y; Rehermann B
    Hepatology; 2012 Jan; 55(1):39-48. PubMed ID: 21898483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection.
    Stegmann KA; Björkström NK; Veber H; Ciesek S; Riese P; Wiegand J; Hadem J; Suneetha PV; Jaroszewicz J; Wang C; Schlaphoff V; Fytili P; Cornberg M; Manns MP; Geffers R; Pietschmann T; Guzmán CA; Ljunggren HG; Wedemeyer H
    Gastroenterology; 2010 May; 138(5):1885-97. PubMed ID: 20334827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.
    Gonzalez VD; Falconer K; Michaëlsson J; Moll M; Reichard O; Alaeus A; Sandberg JK
    Clin Immunol; 2008 Jul; 128(1):46-56. PubMed ID: 18495540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
    Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
    Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
    Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B
    Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.